Facts of Olysio Simeprevir Capsules 150 mg ?
- Medicine Name: OLYSIO
- Generic Name: SIMEPREVIR
- Date of Approval: 25.11.2013
- Company Name: Johnson & Johnson's pharmaceutical division Janssen Pharmaceutica.
Olysio is Indicated for treatment of chronic hepatitis C (CHC); efficacy has been established in combination with peginterferon alfa and ribavirin in patients with HCV genotype 1 infection with compensated liver disease (including cirrhosis)
OLYSIO should not be taken alone.
It is not known if OLYSIO is safe and effective in children under 18 years of age.
OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Screening patients with HCV genotype 1a infection for the presence of virus with the NS3 Q80K polymorphism at baseline is strongly recommended. Alternative therapy should be considered for patients infected with HCV genotype 1a containing the Q80K polymorphism.
OLYSIO (simeprevir) 150 mg capsules are white, marked with “TMC435 150” in black ink. The capsules are packaged into a bottle containing 28 capsules (NDC 59676‑225‑28) or a bottle of 7 capsules (emergency supply; NDC 59676‑225‑07).
Store OLYSIO capsules in the original bottle in order to protect from light. Store OLYSIO capsules at room temperature below 30°C (86°F).